Conference: 2014 International PHA Conference and Scientific Sessions
Release Date: 03.27.2017
Murali Chakinala, M.D.
Washington University School of Medicine
St. Louis, Mo.
To support the attainment of knowledge, competence, and performance, the learner should be able to achieve the following objectives:
Review the latest classifications scheme for pulmonary hypertension
Identify patient groups at increased risk for pulmonary arterial hypertension and the vital role of echocardiography
Translate the non-invasive workup of PH patients into a pre-cath probability for PAH
Emphasize the vital role of right heart catheterization in establishing a PAH diagnosis
This continuing education activity is intended for;
Resolution of Conflict of Interest
PESG has implemented a process to resolve the conflict of interests for each activity. In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, PESG has resolved the conflict by an external content review.
Unapproved/Off-Label Use Disclosure
PESG requires faculty to disclose to the participants:
When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved)
Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Faculty, Planners, Staff Disclosure Information
All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty and planners of this educational activity disclose the following:
Murali Chakinala, M.D., is a consultant for Actelion Pharmaceuticals US, Inc.; Gilead Sciences, Inc.; United Therapeutics Corporation; Bayer HealthCare and Medtronic, Inc. He is on speaker bureaus for Gilead Sciences, Inc.; and United Therapeutics Corporation and receives research support from Actelion Pharmaceuticals US, Inc.; Gilead Sciences, Inc.; United Therapeutics Corporation; Bayer HealthCare; Novartis Pharmaceuticals; Ikaria, Inc.; Medtronic, Inc.; Aires; and Reata Pharameuticals, Inc.
PHA and PESG Staff have no relevant financial relationships to disclose.